23andMe

23andMe
23andMe · Public domain · source
Name	23andMe
Founder	Anne Wojcicki, Linda Avey, Paul Cusenza
Location	Mountain View, California

23andMe is a genetic testing company that provides DNA testing services to consumers, founded by Anne Wojcicki, Linda Avey, and Paul Cusenza in 2006. The company is named after the human genome, which consists of 23 pairs of chromosomes. 23andMe has been at the forefront of the direct-to-consumer genetic testing industry, with investors such as Google Ventures, New Enterprise Associates, and National Institutes of Health. The company has also collaborated with Harvard University, Stanford University, and University of California, San Francisco to advance genetic research.

● History

The history of 23andMe began in 2006, when Anne Wojcicki and Linda Avey founded the company with the goal of making genetic information accessible to consumers. In 2007, 23andMe launched its first DNA testing product, which provided information on an individual's genetic ancestry and genetic traits. The company has since expanded its product line to include health risk and carrier status reports, with the help of Food and Drug Administration and National Institutes of Health. 23andMe has also partnered with Pfizer, GlaxoSmithKline, and AstraZeneca to advance pharmacogenomics research. In 2013, 23andMe received a cease and desist letter from the Food and Drug Administration, which led to a temporary halt in the company's health risk reporting. However, in 2015, 23andMe received FDA clearance to market its Bloom syndrome test, and has since received clearance for several other genetic tests, including those for Parkinson's disease and Alzheimer's disease, with the support of Michael J. Fox Foundation and Alzheimer's Association.

● Products and Services

23andMe offers a range of DNA testing products and services, including ancestry composition, genetic traits, and health risk reports. The company's ancestry composition report provides information on an individual's genetic ancestry, including their haplogroups and ancestral origins. 23andMe has also partnered with National Geographic to offer a genographic project that allows individuals to trace their ancestral migration patterns. The company's health risk report provides information on an individual's genetic risk for certain diseases, such as breast cancer and colon cancer, with the help of American Cancer Society and National Cancer Institute. 23andMe has also collaborated with University of California, Los Angeles and University of Michigan to develop personalized medicine approaches.

● Genetic Testing and Technology

23andMe uses a saliva-based DNA test to collect genetic data from consumers. The company's DNA testing technology is based on single nucleotide polymorphism (SNP) genotyping, which allows for the analysis of thousands of genetic variants. 23andMe has also developed a genotyping chip that can analyze over 600,000 SNPs simultaneously, with the support of Illumina and Thermo Fisher Scientific. The company's genetic testing technology has been validated through studies published in Nature Genetics and New England Journal of Medicine, and has been used in research collaborations with Harvard Medical School and Stanford School of Medicine.

● Controversies and Criticisms

23andMe has faced several controversies and criticisms, including concerns over genetic privacy and the regulation of genetic testing. In 2013, the company faced a class-action lawsuit over its marketing practices, which alleged that the company had made false or misleading claims about its health risk reports. 23andMe has also faced criticism from genetic experts, such as Francis Collins and Eric Lander, who have raised concerns over the interpretation of genetic data and the lack of regulation in the direct-to-consumer genetic testing industry. The company has also been involved in a patent dispute with Illumina over its genotyping technology, and has faced criticism from consumer advocacy groups, such as Consumer Reports and Public Citizen.

● Business and Finance

23andMe has received significant investment from venture capital firms, including Google Ventures and New Enterprise Associates. The company has also partnered with pharmaceutical companies, such as Pfizer and GlaxoSmithKline, to advance pharmacogenomics research. In 2015, 23andMe raised $115 million in Series E funding from investors, including Fidelity Management & Research Company and Casdin Capital. The company has also generated revenue through the sale of genetic data to research institutions, such as National Institutes of Health and University of California, San Francisco, and has collaborated with Bill and Melinda Gates Foundation to advance global health research.

● Impact and Applications

23andMe has had a significant impact on the field of genetics and personalized medicine. The company's DNA testing technology has enabled consumers to access genetic information and make informed decisions about their health and wellness. 23andMe has also contributed to the advancement of genetic research, with studies published in Nature Genetics and New England Journal of Medicine. The company's genetic data has been used in research collaborations with Harvard University, Stanford University, and University of California, San Francisco to advance our understanding of genetic diseases, such as cystic fibrosis and sickle cell anemia, with the support of Cystic Fibrosis Foundation and Sickle Cell Disease Association of America. 23andMe has also partnered with American Heart Association and American Diabetes Association to advance cardiovascular disease and diabetes research.